Effects of 3 years of intravenous pamidronate treatment on bone markers and one mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG)

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 3, 2006, Pages 275-279

  Bayram, Fahri ^a   Tanriverdi, Fatih ^a   Kurtoǧlu, Selim ^a   Atabek, M Emre ^a   Kula, Mustafa ^a   Kaynar, Leyla ^a   Keleştimur, Fahrettin ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Bone mineral density; Osteoporosis pseudoglioma syndrome; Pamidronate therapy

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; PAMIDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BONE DENSITY; BONE PAIN; BONE RADIOGRAPHY; CASE REPORT; CONGENITAL BLINDNESS; CONSANGUINEOUS MARRIAGE; DISEASE SEVERITY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAMILY STUDY; FEMALE; FEMUR NECK; GENE MUTATION; GENETIC SCREENING; HUMAN; LONG BONE; LUMBAR SPINE; MOBILIZATION; NORRIE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PHENOTYPE; SCORING SYSTEM; SIBLING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ABNORMALITIES, MULTIPLE; ADOLESCENT; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; GLIOMA; HUMANS; INJECTIONS, INTRAVENOUS; OSTEOPOROSIS; PAIN; SYNDROME; TREATMENT OUTCOME;

EID: 33645548469     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Frontali M, Stomeo C, Dallapiccola B. Osteoporosis-pseudoglioma syndrome: Report of three affected sibs and an overview. Am J Med Genet 1985; 22: 35-47.
2. Neuhauser G, Kaveggia EG, Opitz JM. Autosomal recessive syndrome of pseudogliomantous blindness, osteoporosis and mild mental retardation. Clin Genet 1976; 9: 324-332.
3. Patel M, Karsenty G. Regulation of bone formation and vision by LRP5. N Engl J Med 2003; 346: 1572-1574.
4. De Paepe A, Leroy JG, Nuytinck L, Meire F, Capoen J. Osteoporosis-pseudoglioma syndrome. Am J Med Genet 1993; 45: 30-37.
5. Swoboda W, Grill F. The osteoporosis pseudoglioma syndrome. Update and report on two affected siblings. Pediatr Radiol 1988; 18: 399-404.
6. Zacharin M, Cundy T. Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr 2000; 137: 410-415.
7. Gong Y, Slee RB, Fukai N, et al; Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107: 513-523.
8. Gong Y, Vikkula M, Boon L, et al; Osteoporosis-Pseudoglioma Syndrome Collaborative Group. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet 1996; 59: 146-151.
9. Lev D, Binson I, Foldes J, Watemberg N, Lerman-Sagie T. Decreased bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome. IMAJ 2003; 5: 419-421.
10. Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: Assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004; 34: 539-546.